Shots:
- BI has entered into a global research collaboration and licensing agreement with Palatin Technologies to develop novel melanocortin receptor agonist for retinal diseases
- As per the deal, Palatin is eligible for ~$327.6M (€280M) in upfront, development, regulatory, & commercial milestone payments, along with tiered royalties on net sales
- Collaboration strengthens Boehringer’s retinal pipeline by advancing melanocortin receptor agonists to target inflammation, vascular dysfunction, & neurodegeneration in diabetic retinopathy (DR) & diabetic macular edema
Ref: Palatin Technologies | Image: Palatin Technologies and Boehringer Ingelheim | Press Release
Related News:- ViVerita Therapeutics Collaborates with Boehringer Ingelheim to Accelerate Discovery of Novel Therapeutic Targets in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
